Group 1 - The company, China National Pharmaceutical Group Modern (国药现代), is currently in the negotiation phase for external research and development collaborations [1] - The company has received clinical approval for two modified new drugs: one is Brivaracetam oral film, primarily used for the treatment of mental disorders and as an adjunct therapy for depression; the other is Topiroxostat tablets, a new uric acid-lowering product, which is an iterative product of Febuxostat [1]